Background and Aims: The genetic contribution to the prognosis of ulcerative colitis [UC] is poorly understood, and most currently known susceptibility loci are not associated with prognosis. To identify genetic variants influencing the prognosis of UC, we performed an Immunochip-based study using an extreme phenotype approach. Methods: Based on the finding that the only association, P discovery-meta <1 × 10 -4 , was located in the human leukocyte antigen [HLA], we focused our analyses on the HLA region. We performed the analysis using HLA imputation data from three independent discovery cohorts of 607 UC patients [243 poor-prognosis and 364 good-prognosis], followed by replication in 274 UC patients [145 poor-prognosis and 129 good-prognosis]. Results: We found that rs9268877, located between HLA-DRA and HLA-DRB, was associated with poor-prognosis of UC at genome-wide significance (odds ratio [OR discovery ] = 1.82; OR replication = 1.55; OR combined-meta = 1.72, p combined-meta = 1.04 × 10 -8 ), with effect size [OR] increasing incrementally according to worsening of prognosis in each of the three independent discovery cohorts and the replication cohort. However, rs9268877 showed no association with UC susceptibility [OR combined-meta = 1.07, p combined-meta = 0.135]; rs9268877 influenced 30-year clinical outcomes, and the presence of the rs9268877 risk allele had a sensitivity of 80.0% and specificity of 38.1% for colectomy. Conclusions: Our results provide new insights into prognosis-associated genetic variation in UC, which appears to be distinct from the genetic contribution to disease susceptibility. These findings could be useful in identifying poor-prognosis patients who might benefit from early aggressive therapy.
Introduction
Genome-wide association studies [GWAS] have identified and confirmed a substantial number of susceptibility loci for ulcerative colitis [UC]. 1, 2 However, the effects of these loci tend to be relatively weak, leaving their clinical utility open to debate. The identification of genetic variants associated with UC progression would have significant clinical utility, allowing clinicians to identify patients at high risk of progressive disease, for whom a more aggressive therapeutic strategy would be appropriate. However, most currently known UC susceptibility variants exhibit weak or inconsistent associations with the clinical course of the disease, [3] [4] [5] suggesting that the genetic variants associated with disease progression might differ from those associated with susceptibility to UC.
Accurate phenotyping and proper strategies for using phenotypic data are critical in identifying prognosis-associated variants. Previous studies aimed at identifying the genetic predictors of UC prognosis were limited by the classification of patients into only two groups, i.e., colectomy versus no colectomy. 3, 6, 7 This classification is simple and easy to apply, but potentially ignores prognostic heterogeneity among patients who do not undergo colectomy, thus preventing robust conclusions.
To identify genetic predictors that impact on the prognosis of UC, we adopted an extreme phenotype approach [8] [9] [10] in the current study. First, we identified patients at opposite ends of the prognostic spectrum and performed a single-centre Korean UC population association analysis in three UC cohorts genotyped using Immunochip v1.0, Immunochip v2.0, and OmniExpress chip, respectively, followed by a meta-analysis of the results. This study, by integrating fine clinical phenotyping data with human leukocyte antigen [HLA] imputation data, provides evidence that a particular HLA variant independently confers poor-prognosis in Korean UC patients.
Materials and Methods

Study population
Among 2147 UC patients who were seen at the Asan Medical Center, Seoul, Korea, 1961 patients were included in the study. The remaining 186 patients who required neither immunosuppressive agents (corticosteroids, thiopurines, or anti-tumour necrosis factor [TNF] agents] nor colectomy over follow-up of less than 5 years, were excluded from the present study because their prognosis was considered undetermined. Of the 1961 patients included in the present study [Supplementary Table S1 , available as Supplementary data at ECCO-JCC online], 1336 patients with any single nucleotide polymorphism [SNP] array data were used in the discovery phase [671 patients in discovery cohort 1, 475 in discovery cohort 2, and 190 in discovery cohort 3], and the remaining 625 patients were used in the replication phase.
Demographic and clinical characteristics of the 1961 subjects are presented in Supplementary Table S1 . All patients were of Korean descent. Diagnosis of UC was made on the basis of conventional clinical, radiological, endoscopic, and histopathological criteria.
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Patient demographic and clinical information was retrieved from the Asan IBD [inflammatory bowel disease] registry, which has been prospectively maintained since 1997 and previously described in detail. 12 For each subject, any changes in clinical information during the follow-up period, including changes in disease extent according to the Montreal Classification, 13 commencement of new medications, and information on surgical procedures, are updated at each clinic visit or at least yearly by IBD clinical specialists.
Patient classification
All cases were treated using a step-up approach, in which therapies with the least toxicity are used first, and subsequent therapies may be administered due to toxicity or lack of response [ Figure 1a ].
14 To reflect the prognostic spectrum, we first classified all 1961 patients into five subgroups based on the highest treatment level reached: 5-aminosalicylates, corticosteroids, thiopurines, anti-TNF agents, or colectomy [ Figure 1b ]. We next selected subgroups of patients at opposite ends of the prognostic spectrum for association analyses. Good-prognosis UC was defined as mild to moderate disease that required neither immunosuppressive agents [corticosteroids, thiopurines, or anti-TNF agents] nor colectomy despite ≥5 years of disease duration. Poorprognosis UC was defined as disease that required anti-TNF agents and/or colectomy regardless of disease duration [ Figure 1c ].
Treatment strategy for UC in Korea
Our treatment strategies for UC have been detailed previously 12, 15, 16 and are based on a step-up approach [ Figure 1a ]. Topical and/or oral 5-aminosalicylates are the first-line therapy to induce and maintain remission in mild to moderate UC. Systemic corticosteroid therapy is used in patients with moderate to severe UC, as well as in those who do not respond to 5-aminosalicylates, and is tapered and discontinued over 2 to 3 months. Thiopurines and, in the event of their failure, anti-TNF agents, are used in steroid-dependent or steroid-refractory patients. In Korea, first-line biologic therapy is seldom reimbursed, and patients need to satisfy strict criteria for reimbursement before they become eligible for anti-TNF agent coverage. 12, [15] [16] [17] For patients to receive government reimbursement, they must exhibit an inadequate response to conventional treatment with corticosteroids and/ or thiopurines, and moderate or severe disease activity.
Genotyping and quality controls
Samples in discovery cohort 1 were genotyped as part of an earlier Immunochip study, 18 in discovery cohort 2 using the Immunochip v2.0 array, and in discovery cohort 3 as part of an earlier GWAS. 19 Genotyping of the replication cohort was conducted using 
Statistical analyses
An analysis using extreme phenotypes was performed using genotype data from three independent discovery cohorts of 607 UC patients Figure S2 , available as Supplementary data at ECCO-JCC online], we focused our subsequent analysis on the HLA region.
HLA imputation
Genotype data from 29M-34M at chromosome 6 were extracted from the post-quality-control datasets and used to impute SNPs, classical HLA alleles, and amino acids using SNP2HLA. 20 The reference panel for imputation, which consists of 413 individuals of Korean origin, has been shown to be accurate for imputing HLA in Koreans; 21 the panel included 10 159 binary markers defined for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, DQB1, and DPB1. Cases and controls were imputed together for 10 159 binary markers separately for three cohorts typed with three different genotyping platforms [Immunochip v1.0, Immunochip v2.0, and GWAS chip]. After imputation, markers with INFO score ≤0.8, MAF <1%, or missing rate >10% of genotypes, in any of the three cohorts were excluded from further analyses. The final set included 4053 SNPs, 87 HLA alleles at four-digit resolution, 58 HLA alleles at two-digit resolution, and 2475 single amino acid variants.
Association testing
Associations for binary markers were tested using probabilistic genotypic dosages that took imputation uncertainty into account. First, an analysis between patients with good-prognosis [n = 493] and poor-prognosis [n = 388] was performed using logistic regression. Second, a stratified analysis based on the highest treatment level reached [n = 1468] was performed with reference to goodprognosis cases [n = 493]. In addition, a case-control analysis was performed to estimate the susceptibility risk compared with unrelated healthy controls [n = 5415; 1185 for Immunochip v1.0, 491 for Immunochip v2.0, and 3739 for GWAS chip]. Conditional logistic regression was performed to identify additional associations. The data were combined using a fixed-effect meta-analysis model [inverse-variance weighted average] in discovery analyses with the three discovery cohorts [Meta discovery ], as well as in joint analysis with the three discovery cohorts and the replication cohort [Meta combined ]. The genome-wide significance threshold was defined as p <5 × 10 -8 .
Adjusting for clinical heterogeneity
Because extensive colitis is a well-established risk factor for colectomy, 12, 22 discovery analysis was performed including a binary model for disease extent at diagnosis (extensive versus non-extensive disease [left-sided colitis or proctitis]) as covariates. To test whether the prognosis of UC was affected by differences in follow-up duration, disease duration was also included as a covariate in the regression.
(a) (b) (c)
Step-up therapeutic strategy 18, 19, 23 PRS were calculated by summing the number of risk alleles multiplied by their corresponding β coefficients. Statistical significance was assessed separately for the three discovery collections and combined using a t-test between poor-prognosis and goodprognosis cases, as implemented in Prizm [GraphPad, San Diego, CA, USA]. We then compared the frequencies of patients with goodprognosis and patients and with poor-prognosis between the first and fourth quartile of PRS. To assess the effect of the PRS on prognosis, effect size was calculated by linear regression of the PRS against the prognosis while adjusting for the effect of other phenotypes. In addition, logistic regression including PRS as covariate was run to estimate the influence of PRS on prognosis of UC for the discovery collection.
Clinical outcomes according to genotype
The influence of the identified variants on long-term outcomes and prognosis, including the cumulative probabilities of colectomy and medication use [anti-TNF agents, thiopurines, and corticosteroids], were assessed in all 1961 patients with UC. The cumulative probabilities were analysed using the Kaplan-Meier method, with differences determined by the log-rank test. To distinguish direct from indirect associations, all regression models were also adjusted for other phenotypes [age of onset, sex, smoking status at UC diagnosis, and disease extent at UC diagnosis]; p <0.05 was considered statistically significant. Statistical evaluations were performed using the packages Prizm and SPSS 21.0 for Windows [IBM SPSS, Ver. 21.0; IBM Co., Armonk, NY, USA].
Candidate genes and functional effects
Genes of interest in the associated region were identified using Ensembl, UCSC Genome Bioinformatics, and GeneCards. ENCODE project data 24 and HaploReg[v4] 25 were used to predict the functional effects of the top associated variants. GTEx 26 was used to investigate expression of quantitative trait loci within genomic regions of interest.
Results
Patient classification based on a step-up treatment strategy
Among 1961 patients, the highest level of treatment was 5-aminosalicylates in 493 patients, corticosteroids in 710 patients, thiopurines in 370 patients, anti-TNF agents in 268 patients, and colectomy in 120 patients [ Figure 1b ]. We categorized patients at opposite ends of the prognostic spectrum for comparison [ Figure 1c ]: 493 patients met the definition of good-prognosis [cohort 1, n = 190; cohort 2, n = 115; cohort 3, n = 59; replication, n = 129], and another 388 patients met the definition of poor-prognosis [cohort 1, n = 160; cohort 2, n = 58; cohort 3, n = 25; replication, n = 145]. The number of follow-up visits per year was 3.1 ± 1.4 for patients with good-prognosis [discovery cohorts: 3.2 ± 1.4, replication cohort: 3.0 ± 1.6] and 6.6 ± 5.0 for patients with poor-prognosis [discovery cohorts: 6.4 ± 3.9, replication cohort: 6.9 ± 6.5].
Variants associated with UC prognosis
To identify genetic predictors of UC prognosis, we first performed association analyses in three UC cohorts genotyped using Immunochip v1.0, Immunochip v2.0, and OmniExpress chip, respectively, followed by a meta-analysis of the results. Based on the finding that the only association p discovery-meta <1 × 10 -4 was located in the HLA [Supplementary Figure S2 , available as Supplementary data at ECCO-JCC online], we focused our subsequent association analyses between binary markers and good versus poor UC prognosis on the HLA region. Discovery meta-analyses of the three cohorts revealed the strongest association between rs9268877 and patients with poor-prognosis who required anti-TNF agents or colectomy [ Figure 2 and Table 1 ; Table 1 and Supplementary Table S6 , available as Supplementary data at ECCO-JCC online). Consistent associations were observed even after adjustments were made for clinical phenotypes, including disease extent and PRS [Supplementary [27] [28] [29] Notably in this regard, TCRβ mutant mice develop spontaneous colitis, 30 and AOAH modulates microbiota-related signals that influence Th17 response and mucosal T-cell immunity. 31 
Clinical outcomes according to rs9268877
To examine the association of rs9268877 with use of medication beyond extreme cases, we performed the association analyses in 1961 patients including 881 extreme cases and 1080 non-extreme cases. When the patients were grouped based on the highest treatment level reached [ Figure 1b] rs9268877 was associated with a higher risk of colectomy and need for medications [ Figure 3 ]. The cumulative probability of colectomy was higher in homozygotes 
UC risk score analysis
To determine whether susceptibility variants collectively influence prognosis, we calculated PRS for each patient using 24 UC risk loci confirmed in Korean populations [Supplementary Table S2] . 18, 19, 23 We found no significant differences in the PRS between the goodand poor-prognosis subgroups [ Figure 4 ; and Supplementary Figure S4 , available as Supplementary data at ECCO-JCC online].
However, there was a statistically significant difference in the percentage of good-prognosis and poor-prognosis patients between the lowest quartile group [Q1: bottom 25%] and the top quartile group [Q4: top 25%] of PRS [Q1: 65.4% versus 34.6% and Q4: 53.0% versus 47.0%, p = 0.04, Figure 4b ]. When the HLA susceptibility SNP rs9271366 was excluded from the calculation of PRS, there was no statistically significant difference in patients with extremes of the distribution [Q1: 65.9% versus 34.1% and Q4: 59.3% versus 40.7%, p = 0.26, Figure 4c ]. We then analysed the effect sizes of PRS for clinical prognosis based on 24 susceptibility loci or 23 loci excluding rs9271366 in the HLA region. Composite PRS from all 24 independent susceptibility signals was associated with prognosis in multiple linear regression analysis. After excluding the HLA susceptibility SNP rs9271366, we did not observe significant associations between prognosis and PRS [Supplementary Table S11, available 
Discussion
By integrating fine phenotyping, including longitudinal data, with HLA imputation data, our results demonstrate that rs9268877 is associated at genome-wide significance with poor-prognosis of UC, but not with susceptibility. To reflect clinical practice, patients were classified according to the highest treatment received, based on a step-up approach. Our patients were enrolled from a registry containing detailed clinical information on medication use and colectomy, enabling this classification. 12, 15, 32 Furthermore, because the Korean national health insurance system requires patients to meet strict criteria for reimbursement of anti-TNF agents, first-line biologic therapy is rare, supporting our classification of patients in need of anti-TNF agents as poor-prognosis. 12, [15] [16] [17] Regarding the disease duration criteria for good-prognosis, previous studies applied criteria of 4 or 10 years. 4, 8, 9 We adopted 5 years, based on a report that two-thirds of the UC patients in remission for the first 5 years after UC diagnosis remained in remission at 10 years. 33 Based on these clinical phenotype definitions, we found that the OR of rs9268877 progressively increased according to treatment level, and confirmed that rs9268877 affects 30-year clinical outcomes.
Although the genetic associations for UC overlap more extensively among different ethnic groups than those for Crohn's disease [CD], 2, 19, 23, 34 the clinical course of UC is generally more favourable in Asian patients than in patients of European ancestry, whereas the course of CD is comparable between Asians and Europeans. 12, 15, 16, 22, 32 The HLA region shows strong evidence of an association with UC in both populations, 2, 35, 36 but the specific HLA alleles associated with UC and their influences on UC prognosis differ between Asians and Europeans.
2 HLA-DRB1*0103 36 was associated with pancolitis and the need for colectomy in European studies, 37 but Asian UC risk allele HLA-DRB1*1502 35 was not associated with prognosis [Supplementary gene, is located ~350 kb away from rs9268877, but was not replicated in the present study. By contrast, rs9268877, identified as a prognosisassociated SNP in this study, was previously identified as a UC susceptibility SNP for Europeans. 36, 38, 39 Recent studies in CD have shown that the genetic contribution to prognosis is independent of the contribution to disease susceptibility. 8, 9, 40 Previous studies focused on susceptibility genes to identify prognosis-associated variants in UC, but failed to demonstrate consistent associations. 3, 4 Our study in Korean UC patients also suggest that the genetic burden of susceptibility variants might not be associated with disease course. Our analysis, based on the extremes of the distribution of genetic burden [the first versus the fourth quartile of PRS], showed no significant differences in percentage of patients with good-and poor-prognosis after excluding the susceptibility HLA SNP. The significant correlation between the PRS and clinical prognosis also disappeared after excluding the susceptibility SNP in HLA region. Therefore, we cannot exclude the possible role of susceptibility variants in the HLA region in UC prognosis. Considering the complex linkage disequilibrium patterns of the HLA region and our modest cohort sizes, further research should be carried out to test if susceptibility and prognosis in UC are determined by the same or different HLA genes. However, our results, together with those of previous studies, 3, 4, 8, 9, 40 suggest that the genetic architecture associated with UC prognosis in non-HLA region is distinct from that of disease susceptibility. Therefore, a great deal remains to be understood about the genetic contribution to prognosis. We speculate that a hypothesis-free approach using a GWAS chip might be a more informative strategy for identifying prognosis-associated variants than the Immunochip array, which was designed for dense genotyping of 186 loci associated with 12 immune-mediated diseases.
This study must be interpreted against the background of its potential limitations. First, our cohort was recruited at a single tertiary referral centre that often handles more severe and refractory cases. Although a single-centre study has an advantage over multicentre studies as a result of more consistent assessment of clinical phenotypes and more reliable longitudinal data, our results need to be replicated in other populations. Second, we only performed in silico analysis of rs9268877, warranting further studies on the biological mechanism underlying the influence of rs9268877 on the prognosis of UC. Third, despite our efforts to address the issue of clinical and genetic heterogeneity, further studies are required to incorporate additional factors, including environmental factors, that might influence the disease course. Fourth, the performance of the rs9268877 'A' allele in sensitivity and specificity might be overestimated, given that it was based on a cohort that included the discovery samples. Finally, our results are based on a step-up approach; consequently, in the era of rapid expansion of the therapeutic armamentarium, emerging therapeutic options might influence the association between rs9268877 and prognosis.
In conclusion, we identified an intergenic variant between HLA-DRA and HLA-DRB that is associated with UC prognosis, but not with susceptibility, and confirmed its clinical impact on 30-year outcomes. This study thus provides new insights into the prognosis of UC, which might be useful for establishing therapeutic strategies and personalised treatment.
Funding
